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Abstract: 
In this study we tested whether the isoquinoline alkaloid berberine can inhibit the growth of 
influenza A. Our experiments showed strong inhibition of the growth of H1N1 influenza A 
strains PR/8/34 or WS/33 in RAW 264.7 macrophage-like cells, A549 human lung epithelial-
derived cells and murine bone marrow derived macrophages, but not MDCK canine kidney cells. 
Studies of the mechanism underlying this effect suggest that berberine acts post-translationally to 
inhibit virus protein trafficking/maturation which in turn inhibits virus growth. Berberine was 
also evaluated for its ability to inhibit production of TNF-α and PGE2 from A/PR/8/34 infected-
RAW 264.7 cells. Our studies revealed strong inhibition of production of both mediators and 
suggest that this effect is distinct from the anti-viral effect. Finally, we asked whether berberine-
containing ethanol extracts of goldenseal also inhibit the growth of influenza A and production 
of inflammatory mediators. We found strong effectiveness at high concentrations, although upon 
dilution extracts were somewhat less effective than purified berberine. Taken together, our 
results suggest that berberine may indeed be useful for the treatment of infections with influenza 
A. 
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1. Introduction 
Influenza A viruses are negative-sense, single stranded RNA viruses which belong to the 
Orthomyxoviridae family [1] and [2]. Each year, seasonal strains of influenza A cause significant 
morbidity and economic losses worldwide. The Centers for Disease Control estimates that 
approximately 23,000 people die annually in the United States from flu-related complications [3]. 
Typically, influenza A infects the tracheal and bronchial epithelial cells as well as alveolar 
macrophages resulting in localized cell damage and the induction of an acute host inflammatory 
response [4], which has been characterized as a “cytokine storm”. This response is the cause of 
the symptoms associated with influenza A infections [5], [6], [7], [8], [9],[10] and [11] and, in addition, can 
lead to destruction of healthy tissue [12]. As a result, infected individuals display heightened 
susceptibility to additional bacterial and viral infections, which are generally the cause of 
morbidity and mortality associated with this virus [4]. 
Current treatments for influenza A infection include both pharmacological and non-
pharmacological approaches. Two types of influenza A specific anti-viral drugs are currently 
available; M2 pump inhibitors such as amantadine and rimantidine, and neuraminidase inhibitors 
including zanamivir and oseltamivir. However, due to side effects and the emergence of drug-
resistant strains [13], vaccination has become the dominant approach for control of this disease. 
Vaccines generally work effectively, but they are contraindicated in neonates and the elderly. 
Also, vaccine production is a complex process based on the predicted emergence of new 
seasonal variants. 
Goldenseal (Hydrastis canadensis) is a plant that has been used for centuries in traditional 
medicine to treat a variety of conditions, including; skin and eye infections, upper respiratory 
disorders, diarrhea, and cancer [14]. Many of the effects of goldenseal have been attributed to the 
isoquinoline alkaloid berberine [15] which is also found in other plants such as barberry (Berberis 
vulgaris), coptis (Coptis chinensis), and Oregon grape (Mahonia aquifolium). Studies with 
berberine have revealed effects on a variety of cellular processes. Berberine has been shown to 
inhibit the growth of certain tumor-derived cell lines [16], [17], [18], [19] and [20] and to prevent the 
growth of certain bacteria [21], [22], [23], [24], [25] and [26]. Berberine can effectively inhibit the growth of 
several viruses [27], [28] and [29] including human cytomegalovirus and herpes simplex virus. 
Berberine has also been shown to inhibit production of cytokines, inflammatory lipids, and nitric 
oxide from macrophages treated with LPS [3] and [30]. Inhibition of cytokine production also 
occurs in vivo in mice treated with LPS, suggesting berberine has potential for the treatment of 
endotoxemia [30] and [31]. 
In this report we have investigated the effects of berberine on infections with influenza A in 
vitro. An abstract published 20 years ago [32], showed that berberine could inhibit the growth of 
influenza A on chicken allantoic membranes, but its effects with mammalian cells had not been 
tested. Therefore, we evaluated berberine for its anti-viral activity against several strains of 
H1N1 influenza A with a number of different murine and human cell types. We also tested 
berberine for its ability to suppress production of TNF-α and PGE2 from infected macrophages. 
Our experiments show strong inhibition of influenza A growth. We also found strong inhibition 
of TNF-α and PGE2 production from infected macrophages. Similar results were seen with 
berberine-containing extracts of goldenseal. Taken together, these results suggest the alkaloid 
berberine and extracts of plants containing berberine may be useful for the treatment of influenza 
A. 
2. Materials and methods 
2.1. Cell lines, media and reagents 
All cell lines were obtained from the American Type Culture Collection (Manassas, VA). RAW 
264.7 cells were cultured in Dulbecco's modification of minimal essential medium (DMEM) 
with 4 mM l-glutamine, 4.5 g/L glucose, and 1.5 g/L sodium bicarbonate with 10% fetal calf 
serum (FCS). A549 cells were cultured in Ham's F-12 nutrient medium with 4 mM l-glutamine 
and 1.5 g/L sodium bicarbonate with 10% FCS. Madin–Darby canine kidney (MDCK) cells were 
cultured in DMEM with 4 mM l-glutamine, 4.5 g/L glucose, and 3.0 g/L sodium bicarbonate and 
supplemented with 10% FCS, 0.2% BSA and 25 mM HEPES buffer. Media, berberine chloride, 
amantadine, and supplements were obtained from Sigma-Aldrich (St. Louis, MO) and Cellgro 
(Manassas, VA). FCS was obtained from Atlanta Biologicals (Atlanta, GA) and Gemini Bio-
products (West Sacramento, CA). Cells were cultured at 37 °C and 5% CO2. 
2.2. Virus propagation and focus forming assays 
A/PR/8/34 and A/WS/33 viruses were originally obtained from the American Type Culture 
Collection (Manassas, VA). Virus stocks were prepared by infecting MDCK cells at a 
multiplicity of infection (moi) of 0.001 (1 infectious particle per thousand cells). The virus was 
added to cells for 30 min in a small volume of serum free virus growth media (DMEM with 
4 mM l-glutamine, 4.5 g/L glucose, and 3.0 g/L sodium bicarbonate and supplemented with 
0.2% BSA, 2 μg/ml Trypsin-TPCK and 25 mM HEPES buffer) followed by the addition of fresh 
virus growth media and incubating for 36–48 h or until cells displayed 90+% cytopathic effect 
(CPE). Cell supernatants were collected, cell debris was removed by centrifugation (1000 rpm 
for 10 min), aliquots prepared, and stored at − 80 °C. For production of experimental 
supernatants, viruses were added to cells at either low (0.002) or high (5) moi following the same 
protocol. Berberine and/or extracts were added with the virus and supernatants were collected at 
the indicated time points. 
Virus titers were determined using a focus forming assay (FFA). MDCK cells were seeded in 24 
or 48 well plates and incubated overnight at 37 °C and 5% CO2. Virus containing cell 
supernatants were added for 30 min followed by the addition of an overlay containing 1.2% 
tragacanth. Plates were incubated for 24 h; cell monolayers were washed with 1× PBS (Sigma, 
St. Louis, MO) and fixed with 1:1 acetone/methanol at − 20 °C overnight. The acetone/methanol 
was removed and plates were allowed to fully dry before blocking in 1% normal horse 
serum/PBS for approximately 1 h. Primary mouse anti-HA monoclonal antibody (Fitzgerald, 
Acton, MA) was diluted 1:3000 in blocking buffer and incubated for 1 h (2.3 μg/ml final Ab 
concentration). Cell monolayers were washed three times with 1× PBS and incubated with 
1:1000 diluted goat anti-mouse IgG-HRP conjugated secondary Ab (Sigma St. Louis, MO) for 
30–45 min (0.8 μg/ml final Ab concentration). Foci were visualized with Vector VIP peroxidase 
substrate kit (Vector Burlingame, CA). Foci were enumerated using GelDoc XR (BioRad 
Hercules, CA) imaging software to determine focus forming units/ml. Titers derived from FFAs 
which are expressed as focus forming units (FFU) are equivalent to plaque forming units (PFU). 
2.3. Preparation of bone marrow derived macrophages 
C57BL/6 murine bone marrow-derived macrophages (BMDM) were obtained from the 
laboratory of Dr. Frank Scholle, PhD, Department of Microbiology, North Carolina State 
University. Cells were cultured in DMEM with 10% FCS, 30% L929 conditioned media, 1× l-
glutamine and 1× non-essential amino acids. Virus inoculations to generate experimental 
supernatants were performed as in Section 2.2 using serum free medium supplemented with 
2 μg/ml Trypsin-TPCK. 
2.4. Immunoblot analysis 
RAW 264.7 cells were plated at a cell density of 5 × 105 cells/60 mm tissue culture dish 
(Corning, Corning, NY) for 24 h, then infected at either low (0.002) or high (5) moi with the 
A/PR/8/34 virus in the absence or presence of 25 μM berberine as described above. At indicated 
times, cell monolayers were washed twice with cold phosphate buffered saline (PBS) (Gibco, 
Carlsbad, CA), lysis buffer added (50 mM HEPES, pH 7.4, 1 mM EGTA, 1 mM EDTA, 0.2 mM 
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 0.2 mM leupeptin, 0.5% SDS), 
lysates collected by scraping, and centrifuged for 30 min at 14,000 rpm. The protein 
concentration for each sample lysate was determined using the Pierce BCA system (Pierce, 
Rockford, IL). Equal protein samples (10 μg) were loaded on 4–12% Bis–Tris gels (Invitrogen, 
Carlsbad, CA) and subjected to electrophoresis using the Novex Mini-Cell System (Invitrogen). 
Following transfer to PVDF membranes, (Millipore, Billerica, MA) membranes were blocked for 
24 h with 5% powdered milk in TBS/0.1% Tween-20 and probed with a primary goat anti-H1N1 
polyclonal antibody (Fitzgerald, Acton, MA) for 1 h and secondary rabbit anti-goat HRP for 
45 min (Southern Biotech, Birmingham, AL) diluted in 1% powdered milk in TBS/0.1% Tween-
20. Bands were visualized using ECL Plus Western Blotting Detection System (GE Healthcare, 
Piscataway, NJ). 
2.5. Immunofluorescence 
RAW 264.7 cells were plated in 8-well chamber slides (Lab-Tek II, Chamber Slide System, 
NUNC, Rochester, NY), incubated for 24 h, and then infected and/or treated with berberine as 
indicated above. Infections were allowed to proceed for indicated times then processed for 
immunofluorescence detection of viral hemagglutinin (HA) protein. Media was removed and 
monolayers were rinsed with PBS 1× and then fixed with 10% formaldehyde for 20 min at room 
temperature. Fixative was removed and monolayers were rinsed with 1× with PBS. Cells were 
then permeabilized with 0.5% Triton X 100 (Sigma, St. Louis, MO) in PBS for 10 min at room 
temperature. Blocking buffer was added (2% BSA, 5% NHS, 10 mM glycine) for 1 h at room 
temperature followed by a 1 h incubation with a viral HA specific monoclonal antibody (mAb) 
(Fitzgerald Acton, MA). The primary mAb was removed, 2 additional PBS washes were 
performed, followed by addition of the secondary rabbit anti-mouse tetramethyl rhodamine iso-
thiocyanate (TRITC) conjugated IgG secondary antibody. Staining was visualized using a Zeiss 
Axioscop 2 plus (Carl-Zeiss Oberkochen, Germany) microscope equipped with a SPOT camera 
(Diagnostic Imaging, Sterling Heights, MI). Images were captured using SPOT software and 
analyzed with Photoshop (Adobe, San Jose, CA) software. 
2.6. ELISA 
TNF-α and PGE2 ELISA kits were purchased from eBioscience (San Diego, CA) and Enzo Life 
Sciences (Plymouth Meeting, PA). Assays were performed according to the manufacturer's 
recommendations. In each case, sample values were interpolated from standard curves. Optical 
density was determined using a PolarStar microplate reader (BMG Labtechnologies, Durham, 
NC). 
2.7. Extract preparation and analysis of berberine content 
Goldenseal (H. canadensis L. Ranunculaceae) roots were cultivated in a hardwood forest in 
western North Carolina, as described elsewhere [26], and a voucher was deposited at the 
Herbarium of the University of North Carolina (NCU583414). Three individual extracts were 
used in these studies; one prepared from a pooled sample of goldenseal roots, one from a pooled 
sample of goldenseal leaves, and one prepared from a single root sample. Extracts were prepared 
in a solvent of 50:50 ethanol:nanopure water at a ratio of 1 ml solvent: 5 g plant material. The 
extracts were analyzed for alkaloid content using LC-MS, as described in detail previously [26], 
and diluted to contain the indicated concentrations of berberine. 
2.8. Cell viability assays 
RAW 264.7 cells (1.5 × 105/well) were plated in 24-well tissue culture dishes in 1 ml DMEM 
and incubated for 24 h. Berberine (25 µM) or a goldenseal extract containing an equivalent 
berberine concentration was added and incubated for an additional 12 or 24 h. Cells were 
harvested with 0.25% Trypsin–EDTA (Sigma, St. Louis, MO) and counted by hemocytometer 
with a 0.04% solution of trypan blue. Cell viability was determined by calculation of the ratio of 
trypan blue stained cells to the number of total cells. 
For DNA cleavage experiments, RAW 264.7 cells (5 × 106/dish) were plated in 100 mm tissue 
culture dishes and incubated for 24 h. Cells were treated with berberine or goldenseal extract as 
above and, in addition, a treatment with cycloheximide (100 μg/ml, Sigma, St. Louis, MO) was 
used as a positive control for the induction of apoptosis. Following 24 h incubation, cells were 
harvested in lysis buffer (50 mM HEPES, pH 7.4, 1 mM EGTA, 1 mM EDTA, 0.2 mM sodium 
orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 0.2 mM leupeptin, 0.5% SDS) and digested 
with proteinase K overnight at 56 °C. Lysates were then extracted using phenol and chloroform 
and DNA precipitated with isopropyl alcohol. Resulting DNA was resuspended in TE buffer 
(10 mM Tris–Cl, pH 8.0. 1 mM EDTA) and treated with 1 μl of RNAse A (Sigma, St. Louis, 
MO) for 30 min at room temperature. DNA (5 μg) was separated by electrophoreses on a 2% 
agarose gel containing ethidium bromide and visualized using BioRad XR Gel documentation 
system (Bio-Rad Hercules, CA). 
3. Results 
3.1. Berberine inhibits the growth of H1N1 influenza A in RAW 264.7 cells and bone marrow 
derived macrophages 
The effect of berberine on the growth of influenza A was first tested with the murine 
macrophage-like cell line RAW 264.7 and the influenza A strain PR/8/34, a mouse-adapted 
strain of influenza A that has been used extensively in studies of influenza A pathogenesis and 
vaccine production. Typically, the replication time for A/PR/8/34 is 6–8 h depending on cell 
type [33] and [34]. Fig. 1A shows the results of a typical time course experiment for the growth of 
this virus in RAW 264.7 cells where infections were performed at a low moi (0.002) to 
approximate conditions of infection in vivo. A total of 103 FFU of virus was added to 
5 × 105 cells in a 1 ml culture. As shown in Fig. 1A, six h after the infection was initiated, levels 
of infectious virus in the culture supernatant had not increased; in fact only small amounts of 
virus were detectable likely representing residual inoculating virus. However, by 12 h we found 
that infectious virus reappeared in the culture supernatant and by 24 h levels of infectious virus 
had increased by 2–3 log units. Our experiments revealed that a concentration of 25 μM 
berberine strongly inhibited virus growth under these conditions ( Fig. 1A). The increase in virus 
titer noted at 12 h was blocked completely and while at 24 h the level of inhibition was 90%. 
Based on these experiments, a series of dose–response curves was performed at the 24 h time 
point. As shown in Fig. 1B, near complete inhibition of the growth of A/PR/8/34 in RAW 264.7 
cells by berberine occurred at concentrations above 1 μM, and the IC50 was 0.01 μM. For this 
virus, berberine was more effective than amantadine, a known anti-influenza compound that 
targets the M2 protein of influenza. Amantadine displayed an IC50 of 27 μM in these 
experiments, which is comparable to the IC50 reported previously (33 μM) [35]. The inhibitory 
effect of berberine on the growth of influenza A was also seen with a second H1N1 virus 
(WS/33) (IC50 = 0.44 μM) ( Fig. 1B). 
 
Fig. 1. Effects of berberine on the growth of influenza A in macrophage-type cells. (A) RAW 
264.7 cells were infected with A/PR/8/34 (moi = 0.002, 1000 FFU) for varying times in the 
absence (○) or presence (□) of 25 μM berberine. Supernatants were collected and virus titers 
determined using a focus forming assay with MDCK cells. Values shown are means +/− S.E.M. 
of triplicate measurements of virus titers from a single representative experiment. (B) RAW 
264.7 cells were infected with A/PR/8/34 (○) or A/WS/33 (∆) at moi = 0.002 for 24 h in the 
presence or absence of varying doses of berberine. Titers were determined as described above 
with % inhibition calculated by comparison with controls. Values shown are from three 
independent experiments with virus titers determined in duplicate in each experiment. Growth of 
strain A/PR/8/34 in the presence of amantadine (⋄) is also shown. (C) Bone marrow derived 
macrophages infected with either A/PR/8/34 or A/WS/33 virus (moi = 0.002, 1000 FFU) in the 
absence or presence of 25 μM berberine for 48 h or 24 h, respectively. Values shown are 
means +/− S.E.M. from three independent experiments with virus titers determined in duplicate 
in each experiment. 
The effect of berberine on the growth of influenza A was also tested with cultures of primary 
macrophages. Bone marrow derived murine macrophages (BMDM) were infected with strains 
A/PR/8/34 or A/WS/33 in the absence or presence of 25 μM berberine. Supernatants were 
harvested after 24–48 h and titers determined using the FFA. As shown in Fig. 1C, berberine 
inhibited the growth of both viruses, but that the effect was variable. With strain A/PR/8/34, 
which produced only 102 FFU after 48 h of growth (after subtracting inoculating dose); we 
measured 30% inhibition by berberine (not statistically significant). On the other hand, we found 
that strain A/WS/33 grew faster, and to higher titers in BMDM. This growth was inhibited 53% 
by berberine at 24 h, which was statistically significant (p = 0.0001). 
3.2. Berberine inhibits the growth of influenza in A549 human lung epithelial cells but not 
MDCK cells 
The effects of berberine were also tested with A549 human lung epithelial cells. These 
experiments were of interest because epithelial cells are a key host target cell for influenza A in 
vivo. As shown in Fig. 2A, berberine completely blocked the growth of strain A/PR8/34 with 
these cells (98% inhibition at 48 h), although we did note that this mouse-adapted viral strain 
grew poorly in this human cell type. Finally, we tested whether berberine could inhibit the 
growth of influenza A in the MDCK canine kidney cell line. This cell line is noted for its highly 
efficient replication of influenza A viruses (note the scale on the y-axis) [36],[37] and [38] and is used 
routinely in plaque and focus forming assays. As shown in Fig. 2B, although we did measure 39 
and 32% growth inhibition with A/WS/33 and A/PR/8/34 strains, respectively, these values were 
not statistically significant. 
 
Fig. 2. Effects of berberine on the growth of influenza A in additional cell types. A) A549 human 
epithelial cells were infected with A/PR/8/34 (moi=0.002, 300 FFU) for 24 or 48 h in the 
absence or presence of 25 μM berberine. Supernatants were collected and viral titers determined 
using a focus forming assay with MDCK cells. B) MDCK cells were infected with influenza 
strains WS/33 or PR/8/34 (moi=0.002, 400 FFU) for 24 h in the presence or absence of 25 μM 
berberine. Values shown are means +/- S.E.M. from three independent experiments with virus 
titers determined in duplicate in each experiment. 
3.3. Studies on the mechanism of viral growth inhibition by berberine 
To gain insight into the mechanism of growth inhibition by berberine, we investigated its effects 
on the expression of several influenza A proteins using a polyclonal goat anti-H1N1 antiserum. 
Four proteins are typically recognized by Abs during influenza A infections, including HA 
(75 kDa), NA (58 kDa), NP (60 kDa), and M (25 kDa)[1]. As shown in Fig. 3A, in proteins 
prepared from cells infected at a low moi (0.002), this antiserum revealed three bands at the 12 
and 24 h time points. Based on predicted molecular weights, the bands running at approximately 
70 and 25 kDa are HA and M proteins, respectively, while the identity of the protein(s) running 
at approximately 60 kDa is not as clear. This band may represent either NA or NP proteins since 
under these SDS-PAGE conditions, their mass differences cannot be resolved. Fig. 3A also 
shows that treatment of infected cells with berberine strongly inhibited production of these 
proteins. 
 
Fig. 3. Effects of berberine on expression of influenza A proteins. RAW 264.7 cells were 
infected with A/PR/8/34 at (A) low moi (0.002) or (B) high moi (5) for indicated times in the 
absence or presence of 25 μM berberine. Expression of influenza A proteins was detected by 
immunoblot assay using a polyclonal goat anti-H1N1 primary antibody and anti-goat-HRP 
secondary antibody. Identification of viral proteins based on predicted molecular weights. Blots 
were reprobed with mAb to β-actin to ensure equal loading of samples. Blots shown are 
representative of two experiments at each multiplicity of infection. 
One possible interpretation of these data is that berberine is blocking virus protein production by 
inhibiting an early step in the virus replication pathway (i.e., entry, uncoating, transcription). 
Alternatively, it may be directly inhibiting the translation of viral proteins. However, since low 
multiplicity infections require several rounds of virus replication, release, and re-infection to 
achieve detectable levels of viral protein (or infectious virus) in the culture, it is also possible 
that berberine is inhibiting a later step in the replication pathway such as protein translocation or 
virus release. Inhibition of these processes would reduce the spread of the virus in culture and 
produce the same result as shown in Fig. 3A. 
To address this question we also examined protein production in high multiplicity infections 
(moi = 5). Under these conditions, each cell is infected at the start of the experiment (super-
infections do not occur with H1N1 influenza A [39]) and proceeds through the early stages of the 
viral life cycle relatively synchronously with viral RNAs and proteins produced simultaneously 
by all cells in the culture. Release of progeny virus to fully infect the cells in culture is not 
required. As shown in Fig. 3B, under these conditions, berberine did not exert a strong effect on 
the production of any of proteins detected. This result indicates that the effects of berberine on 
viral protein production observed under low moi conditions (Fig. 3A) arose from inhibition of 
spread of the virus through the culture not from the inhibition of protein production by individual 
infected cells. The results shown in Fig. 3B also suggest that berberine is interfering with the 
growth of influenza A at a post-translational stage in the virus life cycle. 
We addressed this hypothesis by examining intracellular trafficking of the influenza A HA 
protein, an important aspect of influenza A virus replication that occurs post-translationally. The 
influenza A HA protein follows a well defined translocation process through the endoplasmic 
reticulum (ER) and Golgi en route to the plasma membrane for the formation of virus 
particles [40]. To determine whether berberine interferes with this process, immunofluorescence 
experiments were performed using a mAb against the viral HA protein, in both low and high 
multiplicity infections. As shown in Fig. 4A, 20 h after low moi infections were initiated in the 
absence of berberine, HA displayed a pattern of cell surface expression with weak intracellular 
staining. As shown in Fig. 4B, we found that berberine treatment of similarly infected cells 
produced a change in the pattern of HA staining. Intracellular HA staining was more pronounced 
while surface staining was reduced. Berberine also caused enhanced intracellular HA staining in 
cells infected under high moi conditions (compare Fig. 4C and D). These results suggest that the 
effect of berberine on the growth of influenza A may stem from a post-translational effect on the 
intracellular movement and/or maturation of viral proteins. 
 
Fig. 4. Effects of berberine on HA protein localization. RAW 264.7 cells were grown on 8-well 
chamber slides and infected with strain A/PR/8/34 at low moi (0.002) for 20 h in the absence (A) 
or presence of 25 μM berberine (B). Cells were also infected with A/PR/8/34 at high moi (5) for 
12 h in the absence (C) or presence of 25 μM berberine (D). Cells were fixed, permeabilized and 
HA protein detected using an anti-HA mAb followed by a TRITC-labeled goat anti-mouse 
secondary Ab. Staining was visualized using a Zeiss Axioskop 2 plus fluorescence microscope. 
Magnifications are 40× (A and B) and 100× (C and D). Images are representative of at least five 
experiments performed at each multiplicity of infection. 
Finally, we considered the hypothesis that treatment with berberine is causing cell death and 
thereby reducing production of infectious virus or viral proteins. Previous studies with A549 
cells [41] and THP-1 [42] macrophage-like cell lines have failed to find any cytotoxic effects with 
berberine. In agreement, as shown in Fig. 5A, we did not find any decrease in cell viability when 
RAW 264.7 cells were treated with 25 μM berberine or a goldenseal extract with an equivalent 
berberine concentration. In addition, we did not find any evidence of apoptosis, when assayed by 
DNA fragmentation, in RAW 264.7 cells treated by berberine or goldenseal extract with 
equivalent berberine concentration (Fig. 5B). 
 
Fig. 5. Effect of berberine and goldenseal extract on cell viability. RAW 264.7 cells were treated 
with media, 25 μM berberine, or the goldenseal root extract containing an equivalent berberine 
concentration. (A) Following 12 and 24 h incubation periods cells were harvested and viable 
cells counted by staining with trypan blue. (B) Identically treated cultures were harvested; DNA 
isolated as indicated in the Materials and methods, and separated on 2% agarose gels. A 
treatment with 100 μg/ml cycloheximide was also included as a positive control for induction of 
apoptosis. Results shown are representative of four independent experiments. 
3.4. Berberine inhibits influenza-induced production of TNF-α and PGE2 
In these experiments, we evaluated the effects of berberine on the ability of influenza A to 
induce inflammatory mediators from infected macrophages. We focused on TNF-α, one of the 
major pro-inflammatory cytokines associated with influenza pathogenesis; [43], [44], [45] and [46] and 
PGE2, which recent reports suggest is also responsible for many of the symptoms associated with 
infections by influenza A [47] and [48]. RAW 264.7 cells were infected with strain A/PR/8/34 and 
levels of TNF-α and PGE2 in culture supernatants were determined by ELISA. In preliminary 
experiments with low moi infections, we found that levels of inflammatory mediator production 
were low and inconsistent. Therefore, in these experiments, infections were performed at an moi 
of 5. As shown in Fig. 6A and B, we found that cells infected in this manner produced consistent 
high levels of TNF-α and PGE2, respectively. Both mediators were readily detected at both 12 
and 24 h time points. In contrast, in the presence of 25 μM berberine, we found strong, 
significant inhibition of both TNF-α and PGE2 (Fig. 6A and B) (p < 0.05) at both 12 and 24 h 
time points. 
 
Fig. 6. Effect of berberine on the production of TNF-α and PGE2 from RAW 264.7 macrophage-
like cells. RAW 264.7 cells were infected with strain A/PR/8/34 (moi = 5) 12 or 24 h in the 
presence or absence of 25 μM berberine. Cell supernatants were collected and levels TNF-α (A) 
or PGE2 (B) determined using commercial ELISA kits. Values shown are means +/− S.E.M. 
from two independent experiments with mediator determinations performed in duplicate in each 
ELISA assay. 
3.5. Goldenseal extracts can inhibit influenza growth and block the production of TNF-α and 
PGE2 
Previous results from our laboratories have shown that the activity of botanical compounds may 
differ when tested in purified form or as components of crude extracts [49]. Therefore, we tested 
whether berberine-containing extracts of goldenseal also display anti-viral and anti-inflammatory 
activity. Samples of goldenseal were collected, extracts produced, and levels of berberine 
measured by LC-MS [26]. As shown in Fig. 7A, with extract dilutions containing greater than a 
2.5 μM concentration of berberine, we found complete suppression of virus growth, equivalent to 
the effect of purified berberine. However, when extracts were diluted to contain a concentration 
of 0.25 μM berberine, we found that the extracts were not as effective as purified berberine. As a 
result, IC50 values for extracts were greater than for purified berberine. The H. canadensis root 
extract displayed an IC50 value of 0.22 μM, while an extract produced from H. canadensisleaves 
displayed an IC50 of 0.40 μM. Finally, a dilution of a root extract with a concentration of 25 μM 
berberine was tested for its ability to suppress production of inflammatory mediators. As shown 
in Fig. 7B and C, the root extract strongly inhibited production of TNF-α and PGE2, at levels 
similar to those seen with purified berberine (see Fig. 6). 
 
Fig. 7. Effect of goldenseal extracts on the growth of influenza A and the influenza A-induced 
production of TNF-α and PGE2. (A) RAW 264.7 cells were infected with strain A/PR/8/34 
(moi = 0.002) for 24 h in the absence or presence of 25 μM berberine (○) or a dilution of pooled 
root (∆) or leaf (∇) extracts containing equivalent berberine concentrations. Culture supernatants 
were collected and virus titers determined using a focus forming assay with MDCK cells. 
Percent inhibition of viral growth was calculated as in Fig. 1. Values shown are 
means +/− S.E.M. from three independent experiments with virus titers determined in duplicate 
in each experiment. (B and C) RAW 264.7 cells were infected with strain A/PR/8/34 (moi = 5) 
for 24 h in the absence or presence of a dilution of a single root goldenseal extract containing a 
25 μM concentration of berberine. Levels of TNF-α (B) or PGE2 (C) were determined by ELISA. 
Values shown are means +/− S.E.M. from 5 (12 h) or 2 (24 h) independent experiments with 
mediator determinations performed in duplicate in each ELISA assay. 
4. Discussion 
Our investigations have revealed that berberine can inhibit the growth of influenza A in 
vitro with two different H1N1 strains of influenza A. This effect was observed with two murine 
macrophage type cells (RAW 264.7 macrophage-like cells and normal bone marrow derived 
macrophages) and the A549 human lung epithelial-derived cell line. Dose response curves with 
the A/PR/8/34 virus growing on RAW 264.7 cells revealed several orders of magnitude more 
inhibition by berberine than with amantadine, a well characterized M2 inhibitor. The A/PR/8/34 
virus is known to be relatively resistant to amantadine [50] and its susceptibility to berberine may 
indicate that berberine is working through a distinct mechanism. In addition, we showed that 
berberine can inhibit the influenza A-induced production of TNF-α and PGE2 from RAW 264.7 
macrophages. 
Berberine has been shown to exert a large number of effects on cellular machinery; including the 
reduction of F-actin polymerization [51], moderation of lipid and glucose metabolism [52], direct 
binding to polyadenylic acid [53], and modulation of MAP family kinase activity [54]. To gain 
insight into the effect of berberine on the growth of influenza A, we focused our studies on the 
production of viral proteins. We reasoned that finding inhibitory effects on protein production in 
high multiplicity infections would allow us to concentrate future studies on early events in the 
viral replication cycle, such as entry or transcription of viral genes. Conversely, a lack of effect 
of berberine on protein production would allow us to shift our focus to later events in the 
replication cycle. Our experiments with high moi infections did not reveal an effect of berberine 
on the expression of several different viral proteins, suggesting that berberine is not affecting the 
entry and uncoating of the virus or transcription and translation of viral mRNAs. Berberine also 
likely does not interfere with production of viral genomic RNAs (vRNA, cRNA), since these 
molecules are produced prior to mRNA synthesis. On the other hand, we did detect a change in 
the intracellular position of HA in infected cells that were treated with berberine. The HA protein 
did not display its normal pattern of cell surface staining. Instead, a more punctate intracellular 
pattern was observed. It is possible, therefore, that berberine is acting to block the intracellular 
translocation as HA as it progresses toward the cell surface. Alternatively, berberine may be 
causing HA to misfold, and the punctate intracellular staining we observed arises from 
accumulations of HA targeted for degradation. Finally, we did not observe any evidence of 
berberine-induced cell death. 
Interestingly, we did not find a significant inhibitory effect of berberine on growth of influenza A 
with the MDCK cell line. This cell line is used extensively in vitro for the growth of influenza A, 
and produces many orders of magnitude more virus than any of the other cells we have tested 
( Fig. 2B). It is possible, therefore, that the changes in this cell that allow for highly efficient 
production of influenza A also enable it to be resistant to the effects of berberine. MDCK cells 
are, for example, more efficient in the folding, maturation, and subsequent transport of HA and 
NA proteins, and it is these changes that may endow them with resistance to berberine [55]. The 
inability of berberine to inhibit influenza A growth in MDCK cells may also support a role for 
the host interferon response in the effect of berberine. Seitz et al. have shown that the canine 
interferon response is ineffective against influenza A [56]. Finally, it is also possible that these 
cells are resistant to all effects of berberine because they have elevated levels of an MDR protein 
responsible for berberine efflux. This type of berberine resistance is common among tumor 
derived cell lines [57] and [58]. 
In addition to the effects of berberine on the growth of the virus, we found that berberine could 
strongly inhibit production of TNF-α and PGE2, two mediators linked to the symptoms and 
pathology associated with infections by influenza A. Activation of the host innate response to 
influenza A has been studied extensively [59] and [60]. These studies have shown that recognition of 
influenza A v- and cRNA by host (TLR)-3, -7, -8, RIG-I/MDA5, and NLRs is the key to 
initiating this response [61], [62], [63] and [64]. Collectively, activation of these TLR pathways leads to 
activation of a number of different transcription factors including NF-κB, IRF-3, IRF-7, AP-1 
and IKKε [65], [66], [67], [68] and [69]. The inhibitory effects of berberine on mediator production could 
arise at any number of points in these pathways. Production of a viral RNA ligand could be 
blocked, although this is unlikely since our experiments were conducted under high moi 
conditions, where all cells will contain high levels of viral RNAs and proteins (which we 
confirmed). It is also possible that berberine is interfering with ligand recognition by one of the 
TLRs. As noted above, berberine has been shown to bind polyadenylic acid [53], [70] and [71], and it 
may be that berberine-bound influenza A RNAs do not effectively trigger signaling though one 
or more TLR pathways. It is also possible that berberine is acting downstream in the TLR 
pathways, preventing activation of key transcription factors. Berberine has been shown to block 
the activity of a number of kinases [54], [72], [73] and [74], several of which are known to regulate the 
activity of pro-inflammatory transcription factors. 
The results of our experiments suggest that berberine may be useful for the treatment of 
influenza A. Since berberine is derived from a natural product, many individuals may prefer to 
use a berberine-containing plant extract rather than the purified compound. Therefore, we sought 
to determine whether goldenseal extracts containing berberine also exert the anti-viral and anti-
inflammatory effects. The results of our investigation revealed that at high concentrations, the 
extracts inhibited the growth of influenza A at levels that would be predicted from their 
berberine concentration. However, in more dilute samples; the extracts were less effective than 
would have been predicted from their berberine concentration. The molecular basis for this 
finding is not clear. It is possible that the extracts contain other compounds that reduce the 
available concentration of berberine effectively causing a shift in the dose response curve. 
Alternatively, the extracts may contain compounds that counteract the effects of berberine on the 
infected cell. 
In summary, we have shown that berberine can effectively inhibit the growth of two H1N1 
strains of influenza A with a number of different cell types. We have also shown that berberine 
can inhibit the production of TNF-α and PGE2 from infected RAW 264.7 cells. Experiments 
using animal models will be necessary to determine whether these effects are also seen in vivo. 
However, given that berberine has proven effective for suppressing acute inflammation in mice 
treated with LPS [31], there is no a priori reason why it would not be effective for the treatment of 
influenza A infections in vivo. 
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